316 related articles for article (PubMed ID: 19198835)
1. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
[TBL] [Abstract][Full Text] [Related]
2. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo.
Cha E; Graham L; Manjili MH; Bear HD
Breast Cancer Res Treat; 2010 Jul; 122(2):359-69. PubMed ID: 19826947
[TBL] [Abstract][Full Text] [Related]
3. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma.
Lipshy KA; Kostuchenko PJ; Hamad GG; Bland CE; Barrett SK; Bear HD
Ann Surg Oncol; 1997 Jun; 4(4):334-41. PubMed ID: 9181234
[TBL] [Abstract][Full Text] [Related]
4. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
5. Addition of interleukin-21 for expansion of T-cells for adoptive immunotherapy of murine melanoma.
Zoon CK; Wan W; Graham L; Bear HD
Int J Mol Sci; 2015 Apr; 16(4):8744-60. PubMed ID: 25903148
[TBL] [Abstract][Full Text] [Related]
6. gamma-Interferon plays a key role in T-cell-induced tumor regression.
Tuttle TM; McCrady CW; Inge TH; Salour M; Bear HD
Cancer Res; 1993 Feb; 53(4):833-9. PubMed ID: 8428364
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of bryostatin-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro.
Fleming MD; Bear HD; Lipshy K; Kostuchenko PJ; Portocarero D; McFadden AW; Barrett SK
J Immunother Emphasis Tumor Immunol; 1995 Oct; 18(3):147-55. PubMed ID: 8770770
[TBL] [Abstract][Full Text] [Related]
8. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
[TBL] [Abstract][Full Text] [Related]
9. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
Chin CS; Graham LJ; Hamad GG; George KR; Bear HD
J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126
[TBL] [Abstract][Full Text] [Related]
10. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
11. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
[TBL] [Abstract][Full Text] [Related]
12. Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma.
Zoon CK; Wan W; Graham L; Bear HD
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146052
[TBL] [Abstract][Full Text] [Related]
13. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model.
Parviz M; Chin CS; Graham LJ; Miller C; Lee C; George K; Bear HD
Cancer Immunol Immunother; 2003 Dec; 52(12):739-50. PubMed ID: 12827306
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of bryostatin 1-activated T cells provides long-term protection from tumour metastases.
Tuttle TM; Inge TH; Lind DS; Bear HD
Surg Oncol; 1992 Aug; 1(4):299-307. PubMed ID: 1341264
[TBL] [Abstract][Full Text] [Related]
15. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
Klebanoff CA; Gattinoni L; Palmer DC; Muranski P; Ji Y; Hinrichs CS; Borman ZA; Kerkar SP; Scott CD; Finkelstein SE; Rosenberg SA; Restifo NP
Clin Cancer Res; 2011 Aug; 17(16):5343-52. PubMed ID: 21737507
[TBL] [Abstract][Full Text] [Related]
16. Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma.
Miller CH; Graham L; Bear HD
BMC Immunol; 2010 Nov; 11():54. PubMed ID: 21050466
[TBL] [Abstract][Full Text] [Related]
17. Expansion and tumour specific cytokine secretion of bryostatin-activated T-cells from cryopreserved axillary lymph nodes of breast cancer patients.
Lind DS; Tuttle TM; Bethke KP; Frank JL; McCrady CW; Bear HD
Surg Oncol; 1993 Oct; 2(5):273-82. PubMed ID: 8305969
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy with cells from tumor-draining lymph nodes activated and expanded in vitro.
Haynes C; Graham L; Bear HD
Methods Cell Biol; 2024; 183():355-380. PubMed ID: 38548419
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes.
Rice CD; Baldwin NG; Biron RT; Bear HD; Merchant RE
J Neurooncol; 1997 Mar; 32(1):29-38. PubMed ID: 9049860
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo expansion of tumor-reactive T cells by means of bryostatin 1/ionomycin and the common gamma chain cytokines formulation.
Kmieciak M; Toor A; Graham L; Bear HD; Manjili MH
J Vis Exp; 2011 Jan; (47):. PubMed ID: 21304453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
